FEASIBILITY AND OUTCOME OF FIRST-LINE AUTOTRANSPLANT-BASED TREATMENT IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS AGED > 65 YEARS: MONOCENTRIC RETROSPECTIVE REAL-WORLD ANALYSIS Outcomes of ASCT in NDMM elderly fit patients
Main Article Content
Keywords
real world analysis, Multiple myeloma, autologous stem cell transplantation (ASCT)
Abstract
We performed a monocentric, retrospective real-world analysis (RWA) to evaluate the feasibility and the main results of an autologous stem cell transplantation (ASCT)-based program in a cohort of 90 newly diagnosed multiple myeloma patients aged > 65 years who were deemed eligible to such program on the basis of a simplified frailty score. Seventy-six patients received at least one ASCT and 14 patients received also the second. Median progression-free survival was 42 months and overall survival was 84 months. These results compare well with those of other RWAs, and pave the way to further improvements upon incorporation of an anti-CD38+ monoclonal antibody in the ASCT programs.
Downloads
Abstract 342
PDF Downloads 46
Html Downloads 16
References
2. Bergin K, Wellard C, Augustson B et al. Real-world utilization of ASCT in multiple myeloma (MM): a report from the Australian and New Zealand myeloma and related disease registry (MRDR). Bone Marrow Transplant 2021;56:2533-2543.
3. Cavo M, Tacchetti P, Patriarca F et al. Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study. Lancet 2010;376:2075–85.
4. Facon T, Dimopoulos MA,Meulman N et al. A simplified frailty scale predicts outcomes in transplant-ineligible patients with newly diagnosed multiple myeloma treated in the FIRST (MM-20) trial. Leukemia 2020;34:224-233.
5. Kumar S, Moreau P, Bahlis BJ et al. Daratumumab plus lenalidomide and dexamethasone (D-Rd) vs lenalidomide and dexamethasone (Rd) alone in transplant-ineligible patients with newly diagnosed multiple myeloma (NDMM): updated analysis of the phase 3 MAIA study. Blood 2022;140 (suppl.1):10150-10153.
6. Mateos MV, Dimopoulos M, Cavo M et al. Daratumumab plus bortezomib, melphalan, and prednisone versus bortezomib, melphalan, and prednisone in transplant-ineligible newly diagnosed multiple myeloma: frailty subgroup analysis of ALCYONE. Clin Lymph Myel, Leuk 2021;21:785-791.
7. Mateos MV, San-Miguel J, Cavo M et al. Daratumumab plus bortezomib, melphalan, and prednisone (D-VMP) versus bortezomib, melphalan, and prednisone (VMP) alone in transplant-ineligible patients with newly diagnosed multiple myeloma (NDMM): updated analysis of the phase 3 ALCYONE study. Blood 2022;140 (suppl.1):10157-10159.
8. Moreau P, Attal M, Hulin C et al. Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study. Lancet 2019;394:29-38.
9. Durie BG, Harousseau JL, Miguel JS et al. International uniform response criteria for multiple myeloma. Leukemia 2006;20:1467–73.
Article Sidebar
Article Details
How to Cite
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Transfer of Copyright and Permission to Reproduce Parts of Published Papers. Authors will grant copyright of their articles to the Institute of Hematology, Catholic University, Rome . No formal permission will be required to reproduce parts (tables or illustrations) of published papers, provided the source is quoted appropriately and reproduction has no commercial intent. Reproductions with commercial intent will require written permission and payment of royalties.